NYSE:BAX

57.45
1.83 (3.29%) 1d
0
Showing 1 to 15 of 34 entries
DON'T BUY
Top healthcare pick. Valuation is rich, though the dividend is decent. He will suggest a better stock in Top Picks.
biotechnology / pharmaceutical
DON'T BUY

She owned this a few years ago. It has done well recently, as has the US health sector generally. Its new CEO focused on new product developments that would generate better growth. The company is now fully valued, selling above historical valuation levels. She would consider it on a significant pullback.

biotechnology / pharmaceutical
COMMENT

Dialysis equipment amounts to 40% of their business. Sold his shares too early. They've had a great run. High 24x forward earnings. But the stock warrants a second look. Dividend just under 1% with negative growth and could
continue downward. Nine consecutive quarterly beats.

biotechnology / pharmaceutical
PAST TOP PICK

(A Top Pick Sept 28/16. Up 35%.) Believes he will be holding this for quite a long time. They are the best in the medical devices/medical supply. Expects it might go sideways for a while and it would be a Buy on any weakness.

biotechnology / pharmaceutical
PAST TOP PICK

(A Top Pick June 30/16. Up 42%.) He still likes this. Healthcare is one of the few sectors, if you can deal with the volatility, that is in a secular bull market that began in 2012. He still likes this today, and it is still a Buy.

biotechnology / pharmaceutical
TOP PICK

Very big in kidney medicine. Healthcare is a really good space to be in. One of the few spaces that is in a secular bull market. This company has some pricing power and some really big competitive advantages that are going to be recognized by the market. Dividend yield of 1.1%.

biotechnology / pharmaceutical
TOP PICK

This supplies hospitals with tons of different stuff and there is a focus on renal, things related to the kidneys. Had a sideways move from 2013 to early 2016, and then broke out. Feels it is really good at these prices. They had a really good Q1 and raised their sales and earnings guidance, and increased their expectations for operational improvements. Has a $65 target on this, but thinks that is a little conservative. Dividend yield of 1.15%.

biotechnology / pharmaceutical
COMMENT

Doesn’t follow this closely. Scores particularly well on his valuation metrics. Very high ROE’s at 30%. PE of only 9X, which is a very strong valuation metric for him. It beat recently on earnings. 5.4% dividend yield. However, momentum is where it falls down for him, and it scores in the bottom 10, which keeps him sidelined.

biotechnology / pharmaceutical
BUY

(Market Call Minute) There is a lot thrown away with every operation. It is really expensive stuff. BAX-N makes it. Disposable medical supplies.

biotechnology / pharmaceutical
COMMENT

Medical devices and products. Has a decent dividend yield and has grown is profits at a pretty decent pace. Dealing with some headwinds from a currency perspective. Has been able to hold its profit margins pretty consistently. Good strong balance sheet. Earnings forecasts for next year are trending lower. Trading at about 14X earnings, this is below market multiple. A good grower and this is the kind of stock that eventually rewards investors. You could also look at Thermo Fisher Scientific (TMO-N).

biotechnology / pharmaceutical
DON'T BUY

Used to own it. She saw better opportunities. There is not a lot of pricing leverage because there are strong competitors in that business.

biotechnology / pharmaceutical
BUY

From a valuation perspective, this is one of his favourite stocks. Company has announced that it is going to split itself into 2 main businesses, products for haemophiliacs and a kidney dialysis business. They expect that to happen in 2015. This still offers good value as he thinks the stock is easily worth in the low $80’s.

biotechnology / pharmaceutical
BUY

(Market Call Minute) Likes it here. Growth is good for healthcare stocks.

biotechnology / pharmaceutical
HOLD

Diversified US healthcare stock. Biggest player in Kidney Dialysis. Earnings came in recently a little lighter than the street was looking for but he still likes it.

biotechnology / pharmaceutical
HOLD
Likes it but will not buy more right now. It’s Christine Pool’s stock.
biotechnology / pharmaceutical
Showing 1 to 15 of 34 entries

Baxter International Inc(BAX-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Baxter International Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Baxter International Inc(BAX-N) Frequently Asked Questions

What is Baxter International Inc stock symbol?

Baxter International Inc is a American stock, trading under the symbol BAX-N on the New York Stock Exchange (BAX). It is usually referred to as NYSE:BAX or BAX-N

Is Baxter International Inc a buy or a sell?

In the last year, there was no coverage of Baxter International Inc published on Stockchase.

Is Baxter International Inc a good investment or a top pick?

Baxter International Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Baxter International Inc.

Why is Baxter International Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Baxter International Inc worth watching?

0 stock analysts on Stockchase covered Baxter International Inc In the last year. It is a trending stock that is worth watching.

What is Baxter International Inc stock price?

On 2022-10-04, Baxter International Inc (BAX-N) stock closed at a price of $57.45.